BMC Cancer

CORRECTION

Open Access

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

Farastuk Bozorgmehr[1,2*], Inn Chung[1,2], Petros Christopoulos[1,2], Johannes Krisam[3], Marc A. Schneider[2,4], Lena Brückner[1,2], Daniel Wilhelm Mueller[5], Michael Thomas[1,2] and Stefan Rieken[6]

Correction: BMC Cancer 20, 806 (2020)
https://doi.org/10.1186/s12885-020-07264-8.

Following publication of the original article [1], the authors want to clarify the wording of two sentences.

In the line of the study procedures section "In total, 44 patients will be enrolled per group. After n = 18 patients have been enrolled to the HYPO- or CON-treatment arm, respectively, an interim efficacy analysis for the respective arm will be conducted based on the objective response rate (ORR) at 12 weeks after first durvalumab administration", the sentence was refined to "[…] the objective response rate (ORR), **when the 18th patient in each arm has undergone first radiographic assessment** (at 12 weeks after first durvalumab administration)."

In the study endpoint section, in the line "The ORR evaluated 12 weeks after first durvalumab administration (according to RECIST 1.1) is set as the primary efficacy endpoint.", the sentence changed to "The ORR according to RECIST 1.1 is set as the primary efficacy endpoint."

The online version of the original article can be found at https://doi.org/10.1186/s12885-020-07264-8.

*Correspondence:
Farastuk Bozorgmehr
Farastuk.Bozorgmehr@med.uni-heidelberg.de
[1]Department of thoracic oncology, Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, Heidelberg 69126, Germany
[2]Translational Lung Research Center Heidelberg TLRCH, Member of the german Center for Lung Research DZL, Im Neuenheimer Feld 156, Heidelberg 69120, Germany
[3]Institute of Medical Biometry and Informatics, University Hospital of Heidelberg, Im Neuenheimer Feld 130.3, Heidelberg 69120, Germany
[4]Translational Research Unit (STF), Thoraxklinik at University Hospital of Heidelberg, Röntgenstraße 1, Heidelberg 69126, Germany
[5]Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital, Steinbacher Hohl 2–26, Frankfurt am main 60488, Germany
[6]Department of Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, Göttingen 37075, Germany

Published online: 10 August 2023

References

1. Bozorgmehr F, Chung I, Christopoulos P, et al. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer. 2020;20:806. https://doi.org/10.1186/s12885-020-07264-8.

Publisher's Note